Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
de Bono, JS
MetadataShow full item record
Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, and that such genomic aberrations are synthetically lethal with both poly(ADP)-ribose polymerase inhibition and platinum, has increased interest in the utilisation of these drugs against a subset of these diseases. Here in we report three patients with advanced castration-resistant PCa with HRD defects having exceptional responses to carboplatin.
Version of record
DNA Repair-Deficiency Disorders
Recombinational DNA Repair
Prostatic Neoplasms, Castration-Resistant
Prostate Cancer Targeted Therapy Group
License start date
European urology, 2019, 75 (1), pp. 184 - 192